Community Advisory Board

Readers Rep

Markets:

Overview

News

Currencies

International

Treasuries

HEALTHCARE (NY:XLV)

159.85 -0.40 (-0.25%)

Streaming Delayed Price Updated: 12:52 PM EDT, Jul 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about HEALTHCARE

< Previous 1 2 3 4 5 6 7 8 9

...

43 44 Next >

Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV? ↗

July 21, 2026

FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.

Via The Motley Fool

Topics ETFs

Leading And Lagging Sectors For July 16, 2026 ↗

July 16, 2026

Gainers Symbol Name Price Change ($) Change (%) Volume (NYSE:XLV) State Street Health Care Select Sector SPDR ETF 160.00 1.71 1.08 33.2K (NYSE:XLP) State Street Consumer Staples Select Sector SPDR

Via Benzinga

Topics ETFs

Leading And Lagging Sectors For July 13, 2026 ↗

July 13, 2026

Gainers Symbol Name Price Change ($) Change (%) Volume (NYSE:XLE) State Street Energy Select Sector SPDR ETF 55.8609 0.781 1.41 305.4K (NYSE:XLV) State Street Health Care Select Sector SPDR

Via Benzinga

Topics ETFs

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)? ↗

July 11, 2026

IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns.

Via The Motley Fool

Topics ETFs

Leading And Lagging Sectors For July 7, 2026 ↗

July 07, 2026

Gainers Symbol Name Price Change ($) Change (%) Volume (NYSE:XLV) State Street Health Care Select Sector SPDR ETF 163.9673 2.007 1.23 70.3K (NYSE:XLP) State Street Consumer Staples Select Sector SPDR

Via Benzinga

Topics ETFs

State Street Health Care ETF Tops Invesco Pharma on Cost and Size ↗

July 04, 2026

Compare sector breadth, yield, and recent performance as these two healthcare ETFs take different approaches to growth and income.

Via The Motley Fool

Topics ETFs

SPDR Health Care ETF Tops iShares Biotech in Long-Term Returns ↗

July 02, 2026

Compare portfolio diversity, risk profiles, and income potential as you weigh these two leading healthcare ETFs.

Via The Motley Fool

Topics ETFs

Leading And Lagging Sectors For July 1, 2026 ↗

July 01, 2026

Gainers Symbol Name Price Change ($) Change (%) Volume (NYSE:XLC) State Street Communication Services Select Sector SPDR ETF 108.900 1.770 1.65 18.2K (NYSE:XLV) State Street Health Care Select Sector...

Via Benzinga

Topics ETFs

Leading And Lagging Sectors For June 23, 2026 ↗

June 23, 2026

Gainers Symbol Name Price Change ($) Change (%) Volume (NYSE:XLP) State Street Consumer Staples Select Sector SPDR ETF 83.2775 1.097 1.33 51.0K (NYSE:XLV) State Street Health Care Select Sector SPDR

Via Benzinga

Topics ETFs

Health Care ETFs: XLV Delivers Low Fees and Solid Returns ↗

June 16, 2026

Explore how portfolio concentration and stock count set these healthcare ETFs apart, impacting risk and diversification for investors seeking sector exposure.

Via The Motley Fool

Topics ETFs

Healthcare Giants or Medical Innovators? XLV and PINK Are Built for Different Investors. ↗

June 05, 2026

One fund backs medical breakthroughs and charity, while the other favors industry giants and steady income. Compare their strategies and portfolio makeup.

Via The Motley Fool

Topics ETFs

State Street's Health Care ETF Tops Invesco's on Yield and Returns ↗

June 02, 2026

Expense ratios, dividend yields, and risk profiles set these healthcare ETFs apart. See how their strategies shape long-term performance for investors.

Via The Motley Fool

Topics ETFs

Better Health Care ETF: Fidelity's FHLC vs. State Street's XLV ↗

May 24, 2026

Expense ratios match, but portfolio breadth, yield, and stock concentration set these two healthcare ETFs apart for investors seeking sector exposure.

Via The Motley Fool

Topics ETFs

Healthcare Stocks Are on Fire -- Don't Miss These Opportunities ↗

May 22, 2026

The healthcare sector outperformed the rest of the market over the past week.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

These Stocks Could Be the Biggest Winners of the 2026 Midterms ↗

May 18, 2026

Defense, healthcare, and financial stocks may outperform ahead of midterm elections as investors position for policy shifts

Via MarketBeat

Topics Economy Stocks

1 No-Brainer Healthcare Vanguard ETF to Buy Right Now for Less Than $1,000 ↗

April 13, 2026

Healthcare stocks have been laggards for a while now. The current economic slowdown and structural tailwinds make it much more attractive now.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

The Great Balancing Act: U.S. Gender Labor Gap Closes for the First Time in History

March 26, 2026

The long-standing "gender gap" in the American workforce has effectively closed. According to the Bureau of Labor Statistics (BLS) report released for the first quarter of 2026, the participation rate...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

What Q1 Earnings Could Mean for the S&P 500 Uptrend ↗

March 24, 2026

Via MarketBeat

Topics Stocks

Why AbbVie Stock Looks Like a Dirt Cheap Buy Right Now ↗

March 23, 2026

AbbVie has strong financials, a great dividend, and its stock trades at a modest valuation.

Via The Motley Fool

Topics ETFs Intellectual Property

The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery

March 16, 2026

The biotech sector has found its new North Star in 2026. As of mid-March, Moderna Inc. (NASDAQ: MRNA) has shocked Wall Street with a staggering 83% year-to-date gain, catapulting it to the upper...

Via MarketMinute

Topics Artificial Intelligence Initial Public Offering Stocks

The S&P 500's 3 Best-Performing Stocks so far in 2026 ↗

March 16, 2026

Via MarketBeat

Topics Stocks

HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism ↗

March 05, 2026

In the study, participants receiving a 20-milligram dose of HLP004 alongside standard-of-care treatment experienced an average drop of roughly 10.4 points on the Hamilton Anxiety Rating Scale after six...

Via Stocktwits

The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan

February 27, 2026

As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional...

Via MarketMinute

Topics Artificial Intelligence ETFs

Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue ↗

February 26, 2026

The company generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11.

Via Stocktwits

Topics Artificial Intelligence

PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20 ↗

February 26, 2026

Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’.

Via Stocktwits

Topics Artificial Intelligence

Why Did CASI Stock Plummet 64% Today To Hit An All-Time Low? ↗

February 25, 2026

CASI stated the Nasdaq determined that the company had failed to satisfy the continued listing conditions to remain listed on the Nasdaq Stock Market.

Via Stocktwits

Why Did IXHL Stock Tank Over 32% Today? ↗

February 25, 2026

The company’s board approved a 1-for-30 reverse stock split, effective on February 26.

Via Stocktwits

Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? ↗

February 24, 2026

The FDA has granted Breakthrough Therapy Designation to Larimar’s frataxin protein replacement therapy, nomlabofusp.

Via Stocktwits

VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗

February 24, 2026

Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12.

Via Stocktwits

Why Did IOVA Stock Gain Pre-Market Today? ↗

February 24, 2026

The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel and reported strong fourth-quarter earnings.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

43 44 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

About Us

HEALTHCARE (NY:XLV)

All News about HEALTHCARE